Your browser doesn't support javascript.
New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
Ura, Takehiro; Yamashita, Akio; Mizuki, Nobuhisa; Okuda, Kenji; Shimada, Masaru.
  • Ura T; Department of Ophthalmology and Visual Science, Graduate School of Medicine, Yokohama City University, Yokohama 236-0004, Japan.
  • Yamashita A; Department of Molecular Biology, Graduate School of Medicine, Yokohama 236-0004, Japan.
  • Mizuki N; Department of Ophthalmology and Visual Science, Graduate School of Medicine, Yokohama City University, Yokohama 236-0004, Japan.
  • Okuda K; Department of Molecular Biodefense Research, Graduate School of Medicine, Yokohama City University, Yokohama 236-0004, Japan.
  • Shimada M; Department of Molecular Biodefense Research, Graduate School of Medicine, Yokohama City University, Yokohama 236-0004, Japan. Electronic address: mshimada@yokohama-cu.ac.jp.
Vaccine ; 39(2): 197-201, 2021 01 08.
Article in English | MEDLINE | ID: covidwho-960152
ABSTRACT
The threat of the current coronavirus disease pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is accelerating the development of potential vaccines. Candidate vaccines have been generated using existing technologies that have been applied for developing vaccines against other infectious diseases. Two new types of platforms, mRNA- and viral vector-based vaccines, have been gaining attention owing to the rapid advancement in their methodologies. In clinical trials, setting appropriate immunological endpoints plays a key role in evaluating the efficacy and safety of candidate vaccines. Updated information about immunological features from individuals who have or have not been exposed to SARS-CoV-2 continues to guide effective vaccine development strategies. This review highlights key strategies for generating candidate SARS-CoV-2 vaccines and considerations for vaccine development and clinical trials.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Severe Acute Respiratory Syndrome / Pandemics / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Vaccine Year: 2021 Document Type: Article Affiliation country: J.vaccine.2020.11.054

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Severe Acute Respiratory Syndrome / Pandemics / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Vaccine Year: 2021 Document Type: Article Affiliation country: J.vaccine.2020.11.054